|本期目录/Table of Contents|

[1]朱建强,郑志文,付青峰,等.人工纳米材料在膀胱癌诊疗中的研究进展[J].天津医科大学学报,2022,28(05):563-567.
点击复制

人工纳米材料在膀胱癌诊疗中的研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
28卷
期数:
2022年05期
页码:
563-567
栏目:
综述
出版日期:
2022-09-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2022)05-0563-05
作者:
朱建强; 郑志文; 付青峰; 柳乐意 综述; 张志宏; 徐勇 审校
（天津医科大学第二医院泌尿外科，天津市泌尿外科研究所，天津 300211）
Author(s):
-
关键词:
人工纳米材料; 膀胱癌; 诊断; 治疗
Keywords:
-
分类号:
R737.14
DOI:
-
文献标志码:
A
摘要:
目前，膀胱癌的临床诊疗技术进展缓慢，亟需寻求新的诊疗手段提高其疗效和预后。近年来，人工纳米材料在生物医药领域的研究与应用进展迅速，为恶性肿瘤的诊疗提供了新的视角，弥补了诸多传统技术手段的固有缺陷，具有重要的临床转化应用价值。现对人工纳米材料在膀胱癌诊疗中的应用研究进展进行综述，主要包括其在尿液学检查、膀胱镜检查、影像学检查、病理学检查、手术治疗和药物治疗等方面的研究进展，以期为改善膀胱癌的诊疗现状提供帮助。
Abstract:
-

参考文献/References:

[1] MIRSHAFIEE V，JIANG W，SUN B，et al. Facilitating translational nanomedicine via predictive safety assessment[J]. Mol Ther，2017，25（7）：1522-1530.
[2] SHI J，KANTOFF P W，WOOSTER R，et al. Cancer nanomedicine：progress，challenges and opportunities[J]. Nat rev Cancer，2017，17（1）：20-37.
[3] LENIS A T，LEC P M，CHAMIE K，et al. Bladder cancer：a review[J]. JAMA，2020，324（19）：1980-1991.
[4] LEI Q，ZHAO L，YE S，et al. Rapid and quantitative detection of urinary Cyfra21-1 using fluorescent nanosphere-based immunochromatographic test strip for diagnosis and prognostic monitoring of bladder cancer[J]. Artif Cells Nanomed Biotechnol，2019，47（1）：4266-4272.
[5] ISLAM M A，XU Y，TAO W，et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA[J]. Nat biomed engineer，2018，2（11）：850-864.
[6] ZOU L，LI X，ZHANG J，et al. A highly sensitive catalytic hairpin assembly-based dynamic light-scattering biosensors for telomerase detection in bladder cancer diagnosis[J]. Analyt chem，2020，92（18）：12656-12662.
[7] NOSSIER A I，EISSA S，ISMAIL M F，et al. Direct detection of hyaluronidase in urine using cationic gold nanoparticles：a potential diagnostic test for bladder cancer [J]. Bios Bioel，2014，54：7-14.
[8] YANG Y T，HSU I L，CHENG T Y，et al. Off-resonance sers nanoprobe-targeted screen of biomarkers for antigens recognition of bladder normal and aggressive cancer cells[J]. Analytchem，2019，91（13）：8213-8220.
[9] DAVIS R M，KISS B，TRIVEDI D R，et al. Surface-enhanced raman scattering nanoparticles for multiplexed imaging of bladder cancer tissue permeability and molecular phenotype[J]. ACS nano，2018，12（10）：9669-9679.
[10] FRAN?觭OIS A，BATTAH S，MACROBERT A J，et al. Fluorescence diagnosis of bladder cancer：a novel in vivo approach using 5-aminolevulinic acid（ALA）dendrimers[J]. BJU Int，2012，110（11 Pt C）：E1155-E1162.
[11] BIRKH?覿USER F D，STUDER U E，FROEHLICH J M，et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer[J]. Eur Urol，2013，64（6）：953-960.
[12] DING C，WU K，WANG W，et al. Synthesis of a cell penetrating peptide modified superparamagnetic iron oxide and MRI detection of bladder cancer [J]. Oncotarget，2017，8（3）：4718-4729.
[13] SWEENEY S K，LUO Y，O′DONNELL M A，et al. Nanotechnology and cancer：improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles[J]. Cancer nanotechnol，2016，7：3.
[14] LIU H，MEI C，DENG X，et al. Rapid visualizing and pathological grading of bladder tumor tissues by simple nanodiagnostics [J]. Biomaterials，2021，264：120434.
[15] POLIKARPOV D，LIANG L，CARE A，et al. Functionalized upconversion nanoparticles for targeted labelling of bladder cancer cells[J]. Biomolecules，2019，9（12）：820.
[16] FERREIRA L A B，GARCIA-FOSSA F，RADAIC A，et al. Biogenic silver nanoparticles：in vitro and in vivo antitumor activity in bladder cancer [J]. Eur J Pharm Biopharm，2020，151：162-170.
[17] SUN R，LIU X，LI G，et al. Photoactivated H（2）nanogenerator for enhanced chemotherapy of bladder cancer[J]. ACS nano，2020， 14（7）：8135-8148.
[18] KATES M，DATE A，YOSHIDA T，et al. Preclinical evaluation of intravesical cisplatin nanoparticles for non-muscle-invasive bladder cancer [J]. Clin Cancer Res，2017，23（21）：6592-6601.
[19] HORTEL?觔O A C，CARRASCOSA R，MURILLO-CREMAES N，et al. Targeting 3D bladder cancer spheroids with urease-powered nanomotors [J]. ACS nano，2019，13（1）：429-439.
[20] XU X，LIU K，JIAO B，et al. Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer[J].J Control Release，2020，324：493-504.
[21] WANG B，ZHANG K，WANG J，et al. Poly（amidoamine）-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy[J]. Coll Surf B Bioint，2020，189：110832.
[22] WHANG Y M，YOON D H，HWANG G Y，et al. Liposome-encapsulated bacillus calmette-guérin cell wall skeleton enhances antitumor efficiency for bladder cancer in vitro and in vivo via induction ofAMP-activated Protein Kinase[J]. Cancers，2020，12（12）：3679.
[23] SAMADDAR S，MAZUR J，SARGENT J，et al. Immunostimulatory response of RWFV peptide-targeted lipid nanoparticles on bladder tumor associated cells[J]. ACS Appl Bio Mater，2021，4（4）：3178-3188.
[24] LIANG Y，WANG Y，WANG L，et al. Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer[J]. Bioact Mater，2021，6（2）：433-446.
[25] ZENG S，GAO H，LI C，et al. Boosting Photothermal theranostics via tict and molecular motions for photohyperthermia therapy of muscle-invasive bladder cancer[J]. Adv Healthc Mater，2021，10（24）：e2101063.
[26] LIN T，ZHAO X，ZHAO S，et al. O（2）-generating MnO（2） nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia[J]. Theranostics，2018，8（4）：990-1004.
[27] LIN T Y，LI Y，LIU Q，et al. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer[J]. Biomaterials，2016，104：339-351.
[28] LI G，WANG S，DENG D，et al. Fluorinated chitosan to enhance transmucosal delivery of sonosensitizer-conjugated catalase for sonodynamic bladder cancer treatment post-intravesical instillation[J]. ACS Nano，2020，14（2）：1586-1599.
[29] QI A，WANG C，NI S，et al. Intravesical mucoadhesive hydrogel induces chemoresistant bladder cancer ferroptosis through delivering iron oxide nanoparticles in a three-tier strategy[J]. ACS Appl Mat Interf，2021.
[30] ZHU G，WANG K，QIN H，et al. Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer[J]. J Nanobiotechnol，2020，18（1）：124.
[31] TAN P，CAI H，WEI Q，et al. Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models[J]. Biomaterials，2021，277：121061.
[32] WEI S，GAO J，ZHANG M，et al. Dual delivery nanoscale device for miR-451 and adriamycin co-delivery to combat multidrug resistant in bladder cancer[J]. Biom Pharm，2020，122：109473.
[33] LIN T，ZHANG Q，YUAN A，et al. Synergy of tumor microenvironment remodeling and autophagy inhibition to sensitize radiation for bladder cancer treatment[J].Theranostics，2020，10（17）：7683-7696.

相似文献/References:

[1]陈可新,郝晓东,薄志强,等.≤pT2N0M0膀胱癌根治术后近期复发的影响因素分析[J].天津医科大学学报,2017,23(04):357.
　CHEN Ke-xin,HAO Xiao-dong,BO Zhi-qiang,et al.Influencing factors and prognosis of short-term relapse after radical cystectomy of primary bladder cancer（≤pT2N0M0）[J].Journal of Tianjin Medical University,2017,23(05):357.
[2]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
　MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(05):25.
[3]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566.
[4]刘志飞,张志宏,邢力永,等.RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J].天津医科大学学报,2019,25(01):51.
　LIU Zhi-fei,ZHANG Zhi-hong,XING Li-yong,et al.The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner[J].Journal of Tianjin Medical University,2019,25(05):51.
[5]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
　FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(05):373.
[6]王银蕾,杨 瀚,高 杰,等.PITX2启动子甲基化及其与膀胱癌临床病理的关系[J].天津医科大学学报,2020,26(01):39.
　WANG Yin-lei,YANG Han,GAO Jie,et al.Methylation of PITX2 promoter and relationship with clinical pathology of bladder cancer[J].Journal of Tianjin Medical University,2020,26(05):39.
[7]王玉杰,沈冲,高深,等.长链非编码RNA-FENDRR在膀胱癌组织中的表达及临床意义[J].天津医科大学学报,2020,26(05):445.
　WANG Yu-jie,SHEN Chong,GAO Shen,et al.Expression of long non-coding RNA FENDRR in human bladder cancer tissues and Clinical significance[J].Journal of Tianjin Medical University,2020,26(05):445.
[8]陆益,于佳熙,梁政.氯丙嗪对膀胱癌BT-B细胞迁移功能的影响[J].天津医科大学学报,2022,28(06):621.
　LU Yi,YU Jia-xi,LIANG Zheng.The effect of chlorpromazine on the migration of BT-B cellsin bladder cancer[J].Journal of Tianjin Medical University,2022,28(05):621.
[9]孙晓宇 张志宏 张昌文.膀胱癌类器官模型的研究进展[J].天津医科大学学报,2023,29(05):564.
[10]朱 亮,陈业刚.基于失巢凋亡相关标志物预测膀胱癌患者预后[J].天津医科大学学报,2024,30(01):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]
　ZHU Liang,CHEN Yegang.Prognosis of patients with bladder cancer predicted by biomarker associated with anoikis[J].Journal of Tianjin Medical University,2024,30(05):56.[doi:10.20135/j.issn.1006-8147.2024.01.0056]

备注/Memo

备注/Memo:
基金项目 国家自然科学基金（21806123，22176142，22076138）；天津市青年人才托举工程（TJSQNTJ-2020-07）
作者简介 朱建强（1988-），男，主治医师，博士，研究方向：泌尿系统肿瘤诊疗；通信作者：徐勇，E-mail：yongxutianjin@126.com。
更新日期/Last Update: 2022-09-20